The RGCC Onconomics Plus test is our pioneering step beyond the standard approach to cancer testing and cancer care. The level of intricate genetic information uncovered by this test is unparalleled in the cancer care realm. 

Facing a cancer diagnosis is understandably accompanied by a whirlwind of emotions, a barrage of information, and fear of the unknown. It’s enough to overwhelm and distress anyone. We aim to make this process as supportive and effective as possible.

Our test offers vital information that can help shape a treatment plan targeted at your specific tumor and offer renewed hope for the future.

Traditionally, cancer treatments have often followed a "one-size-fits-all" approach based on different cancer types. This means that treatment decisions typically consider the broad category of cancer rather than exploring the unique genetic makeup of each individual patient's tumor.

While these standardized protocols have undoubtedly saved lives, they sometimes overlook crucial information about specific vulnerabilities within the cancer itself. When treatment isn't specifically tailored to the patient's needs or specific cancer, the risk of inefficient treatment with minimal impact on the cancer as well as the risk of experiencing unnecessary side effects increases. 

For instance, a patient may receive standard chemotherapy when targeted therapies might have been more effective and potentially have had fewer side effects. Or they may continue receiving treatment longer than needed, even if it shows no clear benefit. 

Furthermore, dealing with the physical and emotional burden of such side effects can significantly impact a patient's quality of life during treatment.

Personalized cancer testing offers a new alternative by analyzing a patient's individual genetic and genomic profile to understand the unique characteristics of their cancer. This deeper understanding empowers practitioners to craft a treatment plan tailored precisely to their patient’s cancer.

Imagine treatments designed to directly attack the identified vulnerabilities of the cancer, potentially leading to increased effectiveness in shrinking tumors and preventing their spread. Additionally, by avoiding therapies not relevant to the individual's cancer, personalized testing can potentially minimize unwanted side effects and improve treatment tolerability.

At RGCC, we make this possibility a reality. We're at the forefront of personalized medicine for cancer, a transformative approach that recognizes the unique nature of your cancer. Our advanced Onconomics Plus test unlocks the secrets of your cancer's genetic makeup. This deeper understanding empowers your practitioner to craft a treatment plan tailored precisely to you - all through a convenient and non-invasive liquid biopsy.

Liquid biopsies are a new way to keep track of your cancer. Compared to traditional tissue biopsies, liquid biopsies are not just more cost-effective, they are also far more convenient, causing minimum discomfort and providing quick results.

Moreover, liquid biopsy tests can be repeated over time to monitor your cancer's response to treatment and detect any changes early on.

As our most comprehensive panel, the Onconomics Plus is a simple blood test that is far more powerful than any other cancer test. It helps us understand your cancer's genetic and genomic profile, allowing practitioners to make more informed decisions about your treatment plan. This includes information that can help you select the most effective drugs, measure sensitivity to radiation therapy, and avoid therapies unlikely to benefit you. 

While traditional cancer testing identifies mainly mutations, RGCC's Onconomics Plus test goes a step further. It identifies the unique fingerprint of your individual cancer, offering actionable insights that empower both you and your doctor to make informed decisions about your treatment plan. 

With the Onconomics Plus test, a patient facing a difficult decision about their cancer treatment options can feel empowered. The test results help them identify which treatments are most likely to be effective for their specific cancer and which ones to avoid. This informed decision-making allows every patient to participate actively in their care and choose the path with the best chance for success.

Consider the following examples of how the Onconomics Plus test can help.

• For a patient with breast cancer, our Onconomics Plus test can reveal specific genetic information in the cancer sample. This information empowers their practitioner to choose a therapy tailored to the cancer, potentially leading to better results and fewer side effects compared to a one-size-fits-all approach.
• A patient with lung cancer may receive the Onconomics Plus test and discover that their cancer cells are resistant to some common chemotherapy options. This knowledge could help their practitioner avoid ineffective treatments and focus on therapies that have a higher chance of success, optimizing treatments from the start.
• A prostate cancer patient’s Onconomics Plus test result may show that certain popular natural supplements may not be beneficial for their cancer. This is powerful information since it can save them from unnecessary side effects and potential interactions with other medications. Thus, our test helps the patient focus on truly impactful therapies without wasting precious time.

At RGCC, we understand that personalized care is key to winning the battle against cancer. Here's what sets our tests and protocols apart from the crowd:

• While some prioritize speed and cost, we prioritize accuracy and patient focus. The detailed information provided by our tests offers peace of mind and gives you confidence in your treatment decisions.
• While most laboratories offer diagnostic tests, we provide comprehensive testing for every stage of your cancer journey – from initial baseline to monitoring and recurrence prevention.
• We understand that no two cancers are alike. Our tests are tailored to the cancer’s specific genetic and genomic makeup and physiology, focusing on how your cancer behaves. This ensures the most effective treatment plan possible.
• Most labs use a Positive Selection technique based on specific antibody expression, thus missing a significant portion of circulating cancer cells (CTCs) that do not express these markers. However, our Negative Selection methodology provides a comprehensive CTC count, giving your practitioner a truer picture of your cancer's spread.

RGCC's Onconomics Plus test isn’t a mere diagnostic tool; it is our promise of a partnership in your fight against cancer. And we offer more than just the most comprehensive genetic analysis available. 

Don't settle for a one-size-fits-all approach. Take charge of your health and explore the possibilities of personalized cancer testing with RGCC. Start your journey to empowering information for your cancer treatment by contacting us online.